166 related articles for article (PubMed ID: 38692939)
1. Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis.
Wang J; Li J; Zhong L
Blood Rev; 2024 Jul; 66():101207. PubMed ID: 38692939
[TBL] [Abstract][Full Text] [Related]
2. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
Bhutani D; Leng S; Lentzsch S
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
[TBL] [Abstract][Full Text] [Related]
3. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
4. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.
Ward JE; Ren R; Toraldo G; Soohoo P; Guan J; O'Hara C; Jasuja R; Trinkaus-Randall V; Liao R; Connors LH; Seldin DC
Blood; 2011 Dec; 118(25):6610-7. PubMed ID: 21998211
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of systemic light chain AL amyloidosis.
Bhutani D; Lentzsch S
Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015
[TBL] [Abstract][Full Text] [Related]
7. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability.
Pradhan T; Annamalai K; Sarkar R; Huhn S; Hegenbart U; Schönland S; Fändrich M; Reif B
J Biol Chem; 2020 Dec; 295(52):18474-18484. PubMed ID: 33093170
[TBL] [Abstract][Full Text] [Related]
8. Producing amyloid fibrils in vitro: A tool for studying AL amyloidosis.
Sizova DV; Raiker S; Lakheram D; Rao V; Proffitt A; Jmeian Y; Voegtli W; Batonick M
Biochem Biophys Rep; 2023 Jul; 34():101442. PubMed ID: 36875796
[TBL] [Abstract][Full Text] [Related]
9. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
10. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
11. The Process of Amyloid Formation due to Monoclonal Immunoglobulins.
Morgan GJ; Wall JS
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1041-1054. PubMed ID: 33099422
[TBL] [Abstract][Full Text] [Related]
12. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
Koike H; Katsuno M
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
14. Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy.
Quarta CC; Fontana M; Damy T; Catini J; Simoneau D; Mercuri M; Garcia-Pavia P; Maurer MS; Palladini G
Front Cardiovasc Med; 2022; 9():1073503. PubMed ID: 36606280
[TBL] [Abstract][Full Text] [Related]
15. Therapies for cardiac light chain amyloidosis: An update.
Aimo A; Buda G; Fontana M; Barison A; Vergaro G; Emdin M; Merlini G
Int J Cardiol; 2018 Nov; 271():152-160. PubMed ID: 30223349
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
Badar T; D'Souza A; Hari P
F1000Res; 2018; 7():. PubMed ID: 30228867
[TBL] [Abstract][Full Text] [Related]
17. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis.
Radamaker L; Lin YH; Annamalai K; Huhn S; Hegenbart U; Schönland SO; Fritz G; Schmidt M; Fändrich M
Nat Commun; 2019 Mar; 10(1):1103. PubMed ID: 30894526
[TBL] [Abstract][Full Text] [Related]
18. Methods to study the structure of misfolded protein states in systemic amyloidosis.
Fändrich M; Schmidt M
Biochem Soc Trans; 2021 Apr; 49(2):977-985. PubMed ID: 33929491
[TBL] [Abstract][Full Text] [Related]
19. Supportive Care for Patients with Systemic Light Chain Amyloidosis.
Wong SW; Fogaren T
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1177-1191. PubMed ID: 33099432
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
